Alogliptin — Membership Pricing

Other medications in Diabetes & Metabolism

• Burosumab
• Canagliflozin
• Canagliflozin (Renal)
• Cinacalcet
• Dapagliflozin
• Dapagliflozin (CKD)
• Dulaglutide
• Empagliflozin

About Alogliptin

Alogliptin is a key medication for many individuals managing Type 2 diabetes, helping to regulate blood sugar levels. Understanding its role and how to access it affordably is crucial for consistent treatment. With TheDrugClub, members can often find significant savings on prescriptions like alogliptin, helping you manage your health without the added financial stress.

Understanding Alogliptin: A Key to Type 2 Diabetes Management

Alogliptin is an oral medication primarily prescribed to adults with Type 2 diabetes. It's often used in conjunction with diet and exercise to improve blood sugar control. Unlike Type 1 diabetes, where the body doesn't produce insulin, Type 2 diabetes involves insulin resistance or insufficient insulin production, leading to elevated blood glucose levels. Alogliptin helps address this by enhancing the body's natural ability to lower blood sugar.

How Alogliptin Works to Control Blood Sugar

Alogliptin belongs to a class of drugs called dipeptidyl peptidase-4 (DPP-4) inhibitors. Its mechanism of action involves increasing the levels of incretin hormones in the body, specifically glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones are naturally released after a meal and play a vital role in blood sugar regulation. By inhibiting the enzyme DPP-4, alogliptin allows these incretin hormones to remain active longer, leading to several beneficial effects:

• Increased Insulin Release: When blood sugar levels are high, alogliptin helps stimulate the pancreas to release more insulin.
• Decreased Glucagon Secretion: It also reduces the amount of glucagon, a hormone that raises blood sugar, produced by the pancreas.

These combined actions help to lower both fasting and post-meal blood glucose levels, contributing to better overall diabetes management.

Navigating the Costs of Alogliptin

The cost of prescription medications

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Alogliptin is approved for (FDA label)

Alogliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Alogliptin tablets are a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: Should not be used in patients with type 1 diabetes mellitus. ( 1 ) Limitations of Use Alogliptin tablet is not recommended for use in patients with type 1 diabetes mellitus.

Source: Read the full FDA label on DailyMed. Label effective date: April 11, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Alogliptin (FDA label)

25 mg tablets are light red, oval, biconvex, film-coated, with "TAK ALG-25" printed on one side. 12.5 mg tablets are yellow, oval, biconvex, film-coated, with "TAK ALG-12.5" printed on one side. 6.25 mg tablets are light pink, oval, biconvex, film-coated, with "TAK ALG-6.25" printed on one side. Tablets: 25 mg, 12.5 mg and 6.25 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: b25f155a-1259-47c2-aa3b-7c1356e4c7f6. SPL document ID: 1287590b-abdf-470b-a611-dfb9bc93692a. Label effective date: April 11, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Alogliptin (FDA label)

The following serious adverse reactions are described below or elsewhere in the prescribing information: Pancreatitis [see Warnings and Precautions (5.1) ] Heart Failure [see Warnings and Precautions (5.2) ] Hypersensitivity Reactions [see Warnings and Precautions (5.3) ] Hepatic Effects [see Warnings and Precautions (5.4) ] Severe and Disabling Arthralgia [see Warnings and Precautions (5.6) ] Bullous Pemphigoid [see Warnings and Precautions (5.7) ] Most common adverse reactions (incidence >4%) are nasopharyngitis, headache and upper respiratory tract infection. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals at 1-877-TAKEDA-7 (1-877-825-3327) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: b25f155a-1259-47c2-aa3b-7c1356e4c7f6. SPL document ID: 1287590b-abdf-470b-a611-dfb9bc93692a. Label effective date: April 11, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Alogliptin (FDA label)

Alogliptin tablets is contraindicated in patients with a history of serious hypersensitivity to alogliptin or any of the excipients in Alogliptin tablets. Reactions such as anaphylaxis, angioedema and severe cutaneous adverse reactions have been reported [see Warnings and Precautions (5.3) , Adverse Reactions (6.2) ] . History of serious hypersensitivity to alogliptin or any of the excipients in Alogliptin tablets. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: b25f155a-1259-47c2-aa3b-7c1356e4c7f6. SPL document ID: 1287590b-abdf-470b-a611-dfb9bc93692a. Label effective date: April 11, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Alogliptin (FDA label)

Pancreatitis: There have been postmarketing reports of acute pancreatitis. If pancreatitis is suspected, promptly discontinue alogliptin tablets. ( 5.1 ) Heart failure: Consider the risks and benefits of alogliptin tablets prior to initiating treatment in patients at risk for heart failure. If heart failure develops, evaluate and manage according to current standards of care and consider discontinuation of alogliptin tablets. ( 5.2 ) Hypersensitivity: There have been postmarketing reports of serious hypersensitivity reactions in patients treated with alogliptin tablets such as anaphylaxis, angioedema and severe cutaneous adverse reactions, including Stevens-Johnson syndrome. If hypersensitivity reactions occur, discontinue alogliptin tablets, treat promptly and monitor until signs and symptoms resolve. ( 5.3 ) Hepatic effects: Postmarketing reports of hepatic failure, sometimes fatal. Causality cannot be excluded. If liver injury is detected, promptly interrupt alogliptin tablets and assess patient for probable cause, then treat cause if possible, to resolution or stabilization.

Source: FDA prescribing information (DailyMed). Set ID: b25f155a-1259-47c2-aa3b-7c1356e4c7f6. SPL document ID: 1287590b-abdf-470b-a611-dfb9bc93692a. Label effective date: April 11, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Alogliptin (FDA label)

7.1 Insulin Secretagogues and Insulin Insulin and insulin secretagogues are known to cause hypoglycemia. Coadministration of alogliptin tablets with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower dosages of the insulin secretagogue and insulin to reduce the risk of hypoglycemia [see Warnings and Precautions (5.5) ] .

Source: FDA prescribing information (DailyMed). Set ID: b25f155a-1259-47c2-aa3b-7c1356e4c7f6. SPL document ID: 1287590b-abdf-470b-a611-dfb9bc93692a. Label effective date: April 11, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.